Premium
Effects of P2Y12 inhibition on platelet function in renal transplant patients
Author(s) -
Graff J.,
Klinkhardt U.,
Gossmann J.,
Wahl O.,
Harder S.
Publication year - 2004
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2003.11.024
Subject(s) - p2y12 , medicine , clopidogrel , platelet , pharmacology , platelet activation , urology , aspirin
Renal transplant patients (RTPs) exhibit an increased risk of vascular events under immunosuppressive therapy. In a first study, RTP's under cycloporin (CsA) showed markedly elevated platelet (PLT) activation markers than under tacrolimus (TAC). Since the P2Y12 receptor inhibitor clopidogrel (CLOP) reduces platelet degranulation, we now compared RTPs under TAC (n=21) or CsA (n=21) before and after an experimental treatment with CLOP (75mg/d over 4 weeks). Degranulation [CD 62] and GPIIb/IIIa receptor‐activation [PAC1] were assessed (flow cytometry) with or without stimulation (thrombin‐receptor activating peptide (TRAP).(See Table) At baseline before CLOP therapy CD 62 and PAC1 were significant higher in CsA patients. CLOP lead to significant reduction in all parameters for CsA patients, for TAC only in TRAP‐stimulated samples. It might be proven whether antiplatelet therapy with a P2Y12 inhibitor in CsA ‐treated patients has clinical benefits. Clinical Pharmacology & Therapeutics (2004) 75 , P7–P7; doi: 10.1016/j.clpt.2003.11.024Unstimulated (baseline) TRAP (4μM)pre‐treatment +CLOP pre‐treatment +CLOP CD62 %+ TAC 22 ± 16 17 ± 13 48 ± 21 29 ± 14 *CsA 35 ± 18 # 25 ± 16 * 56 ± 21 41 ± 15 *CD 62 MFI TAC 73 ± 45 58 ± 22 127 ± 59 80 ± 34 *CsA 109 ± 63 # 73 ± 31 * 170 ± 81 # 107 ± 30 *PAC1 MFI TAC 18 ± 13 12 ± 9 * 21 ± 13 11 ± 8 *CsA 28 ± 20 # 17 ± 10 * 32 ± 25 15 ± 10 *# p<0.05 TAC vs. CsA. * p<0.05 before and after CLOP.